What 4 Analyst Ratings Have To Say About Immunogen
Portfolio Pulse from Benzinga Insights
In the last quarter, 4 analysts have provided ratings for Immunogen (NASDAQ:IMGN) with 2 being bullish, 1 somewhat bullish, and 1 indifferent. The company has an average 12-month price target of $23.25, an increase of 12.48% from the previous average price target of $20.67.
November 03, 2023 | 5:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immunogen has received positive ratings from analysts, with an increased 12-month price target. This could potentially boost investor confidence.
Analyst ratings often influence investor sentiment. The positive ratings and increased price target for Immunogen suggest a positive outlook for the company, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100